Aarey Drugs & Pharm Ltd

NSE: AAREYDRUGS · Pharmaceuticals · sector

₹103.19NSE close 2026-10-26

Key numbers

Market cap₹294 cr

Price₹103.19

52w high / low₹115 / ₹50

P/E56.4xSector median 27.9x

P/B1.9xSector median 2.9x

Book value₹52.9

Dividend yield–Sector median 0.48%

ROE2.9%Sector median 11.7%

ROCE4.9%Sector median 12.3%

OPM1.6%Sector median 14.0%

Debt / equity0.33xSector median 0.16x

EV/EBITDA50.4xSector median 18.6x

Interest cover1.8x

Current ratio1.81x

Sales growth 3y+96.3%Sector median +9.6%

Profit growth 3y+100.2%Sector median +13.3%

PEG0.60x

Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1 cr vs borrowings ₹50 cr (FY26): borrowings are higher by ₹49 cr.
Operating profit covered interest 1.8x in the last 12 months.
Promoter holding fell by 3.35 percentage points in a year, to 41.45% (2026-09-30).
Operating cash flow was below net profit in 1 of the last 5 years (FY23).
Revenue was higher than a year earlier in 1 of the last 4 quarters.
Other income was 150% of net profit in the last 12 months.
Debtor days went from 0 (FY24) to 100 (FY26).
No dividend in the last 5 financial years.
Price ₹103.19 on 2026-10-26: -10.1% from the 52-week high, +105.1% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹112.91 · low ₹33.54

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	105	134	108	102	84	96	189	45
EBITDA	4	2	-5	2	3	-2	4	1
OPM %	3.5%	1.6%	-4.5%	1.7%	3.1%	-1.6%	2.3%	3.0%
Other income	0	1	8	2	1	4	-0	2
Net profit	2	1	0	1	1	1	2	1
EPS (₹)	1.14	0.26	0.04	0.48	0.72	0.20	0.55	0.36
Revenue YoY					-20.0%	-27.9%	+75.3%	-56.3%
Profit YoY					-36.3%	-20.8%	+231.9%	-25.5%

Standalone figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	493	62	396	474	472	415
EBITDA	11	2	4	2	7	7
Net profit	8	0	5	4	4	4
EPS (₹)	2.72	0.19	1.84	3.27	1.39	1.83
Revenue growth		-87.3%	+533.3%	+19.8%	-0.4%	-7.7%
Profit growth		-93.5%	+855.1%	-14.1%	-1.2%	+0.4%
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+96.3%	–	-7.7%
Net profit	+100.2%	–	+0.4%
EPS	+94.1%	–	–
Share price	–	+32.9% (2y)	+25.8%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	117	133	138	150
Borrowings	–	38	31	35	50
Cash & equivalents	–	1	2	1	1
Total assets	–	291	305	238	297
Fixed assets	–	14	15	16	26
Capital work in progress	–	0	–	0	0
Investments	–	0	0	0	2
Receivables	–	190	0	130	130
Inventory	–	29	35	45	42
Payables	–	127	129	54	82

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	19	-39	8	10	10
Cash from investing	24	11	-7	-6	-12
Cash from financing	4	-23	4	-4	2
Capex	2	1	0	0	12
Free cash flow	16	-40	8	10	-2

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	0.4%	3.5%	2.9%	2.6%
ROCE %	–	0.8%	5.9%	5.8%	5.2%
Debtor days	–	1,109	0	100	100
Inventory days	–	179	33	36	33
Payable days	–	793	123	43	66
Cash conversion cycle (days)	–	495	-90	93	67
Working capital days	–	599	-65	90	91

Shareholding

Holder	% (2026-09-30)
Promoters	41.45%
FIIs	4.27%
DIIs	1.44%
Public (non-institutions)	52.83%

Quarter	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Aug 2026	Sep 2026	Sep 2026
Promoters %	44.80%	44.80%	39.06%	37.71%	37.71%	42.79%	41.45%	41.45%

Promoter group	%
Bina Rajesh Ghatalia	14.13%
Mihir Rajesh Ghatalia	9.98%
Nimit Impex	6.31%
Nimit Rajesh Ghatalia	5.18%
Mira Mihir Ghatalia	2.95%
Ekta Nimit Ghatalia	1.57%
Mihir Rajesh Ghatalia HUF	0.77%
Rajesh Pranlal Ghatalia	0.57%
Suraj Tradelinks	0.00%
Enam Organics India Limited	0.00%
Worth Investment and Trading Company Limited	0.00%

Public holders above 1%	%
Elysian Wealth Fund	2.78%
Krishnamurthy C G	1.57%
Suvi Rubber Pvt Ltd	1.47%
Shree Salasar Properties And Finance Private Limited	1.44%
Chetan Kirtibhai Mehta	1.25%
Richa Bothra	1.21%

13,485 shareholders. Pledged: – of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
AAREYDRUGS	₹294 cr	56.4x	1.9x	2.9%	4.9%	1.6%	+96.3%	–

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2024-09-23	Other	Annual General Meeting
2023-08-29	Other	Annual General Meeting
2022-09-22	Other	Annual General Meeting
2021-09-02	Other	Annual General Meeting

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	AAREYDRUGS
BSE code	524412
ISIN	INE198H01019
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.